Attempts have been made to reveal the true nature of a range of puzzling diseases within gastroenterology and hepatology using different kinds of omics, namely genomics, transcriptomics, proteomics, and metabonomics [1, 2] . Due to expensive, cumbersome, and time-consuming analytical techniques and lack of adequate biostatistical tools to handle multi-omics data, a single omics approach has typically been applied to a given disease. As an example, large genome-wide association studies have so far associated >240 genomic loci variants to inflammatory bowel disease (IBD) [3] . Unfortunately, these explain a merely 15-20% of the actual disease phenotype [4] , and the efforts made to identify genotype-phenotype relations within IBD and a range of other diseases have been surprisingly disappointing. The obvious explanation for this is the various downstream regulatory processes that take place from the genome to the metabolome (i.e., epigenome, epitranscriptome, epiproteome) and the concomitant interactions with the exposome (e.g., nutrients) and most importantly with the microbiome. Thus, the complexity of the network increases towards the metabolome, and the read-out from the metabolome comprises information that is much closer to a meaningful patho/physiological phenotype.
Whereas the above-mentioned studies deliver original insight into molecular processes at play in relation to specific conditions, Takis et al. [8] used metabonomics based on nuclear magnetic resonance (NMR) spectroscopy to create a panel of biomarkers capable of differentiating between patients with acute upper abdominal pain versus diffuse abdominal pain. Based on a single blood sample and NMR fingerprinting, the 64 patients included, who were all admitted to the emergency room due to severe abdominal pain, could be segregated into the two distinct groups, namely upper abdominal pain (gallstones, cholecystitis, pancreatitis) versus diffuse abdominal pain (intestinal ischemia, strangulated or mechanic obstruction), with an acceptable discriminant accuracy of >70-85%. Nevertheless, no single metabolites could be held accountable for the discrimination, which is not surprising given the heterogeneity of the two groups; however, this clearly illustrates the potential of metabonomics for biomarker identification and as a diagnostic tool.
There is no doubt that metabonomics and its integration with other omics will evolve as novel reliable techniques in the years to come, bringing great benefits to patients in terms of diagnosis and treatment. However, scientists need to simplify the techniques applied before such an option might be introduced into real-world routine clinical settings.
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